Author: claimsbot

1. A physically and chemically cured membrane composition comprising an inlet face and an outlet face, and incorporating ingredients comprising:
a) at least one membrane compound comprising a plurality of ester moieties and a plurality of N-containing backbone moieties, wherein each N-containing moiety is at least divalent, wherein the at least one compound comprises ester repeat units of Formula I:
and at least one second repeat unit selected from the esteramide units of Formula II andor the esteramide units of Formula III, and optionally at least one repeat unit of the ester-urethane units of Formula IV:
wherein:
each R is independently selected from a C2-C20 non-aromatic hydrocarbylene group, a C2-C20 non-aromatic heterohydrocarbylene group, or a polyalkylene oxide group having a group molecular weight of from about 100 to about 5000 gmol;
each R1 independently is a bond or a C1-C20 non-aromatic hydrocarbylene group;
each R2 independently a C1-C20 non-aromatic hydrocarbylene group;
each RN independently is \u2014N(R3)\u2014Ra\u2014N(R3)\u2014, where each R3 is independently H or a C1-C6 alkyl or RN is a C2-C20 heterocycloalkylene group containing at least two nitrogen atoms;
w+x+y+z=1, 0<w<1, and at least one of x and y is greater than 0;
Ra is a C2-C20 non-aromatic hydrocarbylene group; and
n is at least 1 and has a mean value less than 2;
and
b) at least one azide crosslinking agent that chemically crosslinks the at least one membrane compound.
2. The composition according to claim 1, wherein the at least one compound has a number average molecular weight in the range from 2000 to 50,000.
3. The composition according to claim 1, wherein the at least one compound is nonaromatic.
4. The composition according to claim 1, wherein a repeating unit according to Formula I has a structure according to Formula V and a repeating unit according to Formula II has the structure according to Formula VI:
wherein q and r are 4, n is 2, p is 5, x is 0.18 and y is 0.82.
5. The composition according to claim 1, wherein the azide crosslinking agent comprises a compound represented by the following formula
(N3)m\u2014R10
wherein m is 1 to 6 and R10 is an m-valent moiety that may be aryl or nonaryl; saturated or unsaturated; linear or branched or cyclic; andor substituted or unsubstituted.
6. The composition according claim 1, wherein the azide crosslinking agent comprises a compound represented by the following formula
wherein each Ro and R11 independently is a divalent linking group that may comprise a heteroatom such as one or more of O, S, P, or the like and that may be linear, branched, cyclic, polycyclic, fused ring, or the like; with the proviso that each Ro independently may be a single bond.
7. The composition according to claim 6, wherein R11 is a linear, branched, cyclic, or polycyclic hydrocarbyl moiety of the formula
wherein v is 1 to 10; each R12 independently is H, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms.
8. The composition according to claim 6, wherein each of Ro and R11 independently is a linear, branched, cyclic, or polycyclic alkoxylene moiety of the formula
\u2014(OR13)q\u2014
wherein q is 1 to 10; and R13 is a divalent alkylene moiety that may be linear, branched, cyclic, or polycyclic.
9. The composition according to claim 6, wherein each Ro and R11 independently is selected from oxygen,
10. The composition according to claim 1, wherein the azide crosslinking agent comprises a compound having a fused ring structure.
11. The composition according to claim 1, wherein the azide crosslinking agent comprises a substituted or unsubstituted material according to the formula
12. The composition according to claim 1, wherein the azide crosslinking agent comprises a substituted or unsubstituted material according to the formula
13. The composition according to claim 1, wherein the azide crosslinking agent comprises a substituted or unsubstituted material according to the formula N3\u2014(R13O)q\u2014Ro\u2014N3, wherein Ro is selected from oxygen,
R13 is a divalent alkylene moiety that may be linear, branched, cyclic, or polycyclic, and q is 1 to 10.
14. A method of separation, comprising the steps of:
(a) providing a separation membrane derived from ingredients comprising at least one membrane compound comprising a plurality of ester moieties and a plurality of N-containing, divalent backbone moieties and at least one azide crosslinking agent according to claim 1, wherein the membrane compound comprises ester repeat units of Formula I:
and at least one second repeat unit selected from the esteramide units of Formula II andor the esteramide units of Formula III, and optionally at least one repeat unit of the ester-urethane units of Formula IV:
wherein:
each R is independently selected from a C2-C20 non-aromatic hydrocarbylene group, a C2-C20 non-aromatic heterohydrocarbylene group, or a polyalkylene oxide group having a group molecular weight of from about 100 to about 5000 gmol;
each R1 independently is a bond or a C1-C20 non-aromatic hydrocarbylene group;
each R2 independent C1-C20 non-aromatic hydrocarbylene group;
each RN independently is \u2014N(R3)\u2014Ra\u2014N(R3)\u2014, where each R3 is independently H or a C1-C6 alkyl or RN is a C2-C20 heterocycloalkylene group containing at least two nitrogen atoms;
w+x+y+z=1, 0<w<1, and at least one of x and y is greater than 0;
Ra is a C2-C20 non-aromatic hydrocarbylene group; and
n is at least 1 and has a mean value less than 2;
(b) using the membrane to separate components of a feed mixture to provide a first separation product that is enriched with respect to an ingredient of the feed mixture and a second separation product that is depleted with respect to the feed ingredient.
15. A purification system comprising:
(a) a feed mixture comprising at least one acid gas and at least one nonpolar gas;
(b) a membrane having an inlet face and an outlet face, wherein the membrane is derived from ingredients comprising at least one compound comprising a plurality of ester moities and a plurality of N-containing, divalent backbone moieties and at least one azide crosslinking agent according to claim 1; and
(c) a pressure differential between the inlet face and the outlet face effective to provide a first separation product that is enriched with respect to the acid gas relative to the feed mixture and a second separation product that is depleted with respect to the acid gas relative to the feed mixture when the feed mixture is caused to contact the membrane.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A testing system configured for testing a device, comprising
a plurality of different models of oscillographs each having a general purpose interface bus (GPIB) port;
a connection cord having a universal serial bus (USB) connector at a first end, and a GPIB connector at an opposing second end for selectively connecting to a GPIB port of one of the oscillographs;
a computer comprising:
a USB port for connection with the USB connector of the connection cord,
an oscillograph model displaying module configured to display a plurality of oscillograph models for a user to select according to the model of the oscillograph which is connected to the computer through the connection cord;
an oscillograph driving module configured for loading an oscillograph driver corresponding to the selected oscillograph model;
a storage module configured for storing a plurality of codes for each of the different models of the oscillographs, the codes being associated with a plurality of testing functions;
a testing interface module configured for transmitting the codes to the oscillograph connected to the computer, thereby driving the oscillograph connected to the computer to perform the associated testing functions to test the device.
2. The testing system as described in claim 1, wherein the computer further comprises a test result obtaining module, the test result obtaining module is configured for obtaining and outputting the test result to the user.
3. The testing system as described in claim 1, wherein the computer further comprises an instruction module, the instruction module stores a plurality of instructions, the instruction are identifiable by the corresponding oscillograph, the testing interface module further is configured for transmitting the instructions to the oscillograph to execute the instructions.

1. A miscarriage kit comprising:
at least one under padbed liner configured to be positioned on a surface, the under padbed liner having a bottom layer and a top layer, wherein the top layer is designed to absorb bodily fluids, and wherein the bottom layer protects the surface from bodily fluids that soak through the top layer;
at least one sanitary napkin;
at least one towel;
at least one pair of gloves;
at least one specimen pan for receiving human tissue; and
at least one container for holding fetal remains for legal disposition.
2. The kit of claim 1, wherein the container for holding pregnancy remains is a spill-proof, sanitary container.
3. The kit of claim 1, further comprising a list of one or more items for use in helping the human in at least one of managing, controlling, cleaning up, handling, acquiring samples of, and disposing of the body fluids discharged before, during, or after a miscarriage based on the human’s going through a miscarriage.
4. The kit of claim 1, further comprising one or more items used in helping the human in at least one of managing, controlling, cleaning up, handling, acquiring samples of, and disposing of the body fluids discharged before, during, or after a miscarriage based on the human’s going through a miscarriage.
5. The kit of claim 1, further comprising one or more items used in helping the human in at least one of managing, controlling, cleaning up, handling, acquiring samples of, and disposing of the body fluids discharged before the human experiences a miscarriage.
6. The kit of claim 1, further comprising one or more items used in helping the human in at least one of managing, controlling, cleaning up, handling, acquiring samples of, and disposing of the body fluids discharged substantially during the period the human experiences a miscarriage.
7. The kit of claim 1, further comprising one or more items used in helping the human in at least one of managing, controlling, cleaning up, handling, acquiring samples of, and disposing of the body fluids discharged after the miscarriage.
8. The kit of claim 1, wherein the human tissue comprises fetal remains.
9. The kit of claim 1, wherein the under padbed liner comprises an absorbent padding on the top surface and an impermeable backing on the bottom surface.
10. A miscarriage kit comprising:
at least one under padbed liner configured to be positioned on a surface, the under padbed liner having a bottom layer and a top layer, the top layer is designed to absorb bodily fluids, and wherein the bottom layer protects the surface from bodily fluids that soak through the top layer;
at least one sanitary napkin;
at least one towel;
at least one pair of gloves;
at least one specimen pan, wherein the specimen pan is configured to fit inside the rim of a toilet and further includes an upper rim configured to allow the upper rim to rest atop the toilet rim, the specimen pan having an opening positioned and sized to receive fluids and human tissue from a miscarriage, and wherein the specimen pan is comprised of a durable material; and

wherein the specimen pan provides a measurement guide for measurement of fluid loss; and
at least one container for holding fetal remains for legal disposition, wherein the container is opaque.
11. The miscarriage kit of claim 10, wherein the measurement guide allows the woman to measure fluid loss to assist her doctor in diagnosing a hemorrhage.
12. The miscarriage kit of claim 10, wherein the measurement guide shows one or more of the following measurements in any combination
fluid ounces;
cubic centimeters (cc).
13. A miscarriage kit comprising:
at least one under padbed liner;
at least one sanitary napkin;
at least one towel;
at least one pair of gloves;
at least one specimen pan for receiving human tissue; and
at least one container for holding fetal remains for legal disposition; and
at least one thermometer.
14. The miscarriage kit of claim 13, further comprising at least one protective undergarment.
15. The miscarriage kit of claim 1, wherein the bottom layer of the under padbed liner is impermeable to bodily fluids.
16. The miscarriage kit of claim 1, wherein the bottom layer of the under padbed liner is polypropylene.
17. The miscarriage kit of claim 1, wherein the under padbed liner further comprises a non-skid feature.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of Formula I
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug;
wherein R1 is a) \u2014(C1-C6)alkyl optionally substituted with \u2014CF3, b) \u2014C\u2261C\u2014CH3, c) \u2014C\u2261C\u2014Cl, d) \u2014C\u2261C\u2014CF3, e) \u2014CH2O(C1-C4)alkyl optionally substituted with \u2014CF3 or f) \u2014CF3;
R2 is a) \u2014(C1-C5)alkyl, b) \u2014(C2-C5)alkenyl or c)-phenyl optionally substituted with one of the following: \u2014OH, \u2014NR8R9, \u2014NR8\u2014C(O)\u2014(C1-C4)alkyl, \u2014CN, \u2014Z-het, \u2014O\u2014(C1-C3)alkyl-C(O)\u2014NR8R9, \u2014NR8\u2014Z\u2014C(O)\u2014NR8R9, \u2014Z\u2014NR8\u2014SO2\u2014R9, \u2014NR8\u2014SO2-het, \u2014O\u2014C(O)\u2014(C1-C4)alkyl or \u2014O\u2014SO2\u2014(C1-C4)alkyl;
Z for each occurrence is independently \u2014(C0-C4)alkyl;
R3 is a) \u2014(C1-C6)alkyl, b) \u2014Z\u2014NR4R5 or c) \u2014Z-het;
R4 and R5 are each independently a) hydrogen or b) \u2014(C1-C3)alkyl;
het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with one to three R6;
R6 is a) \u2014(C1-C6)alkyl optionally substituted with one to three R7, b) \u2014Z\u2014NR8R9 or c) \u2014Z\u2014C(O)\u2014NR8R9;
R7 for each occurrence is independently a) halo, b) \u2014OH, c) oxo or d) \u2014O(C1-C6)alkyl;
R8 and R9 for each occurrence are independently a) \u2014H or b) \u2014(C1-C3)alkyl;
or R8 and R9 are taken together with N to form het;
n is one to three;
provided that:
1) when R1 is \u2014C\u2261C\u2014CH3, R2 is phenyl and n is one, then R3 is other than \u2014CH2\u2014N(CH3)2, \u2014(CH2)2\u2014N(CH3)2, \u2014CH2-piperidinyl or \u2014(CH2)2-morpholinyl;
2) when R1 is \u2014(CH2)2\u2014CH3, R2 is phenyl and n is one, then R3 is other than -t-butyl or -3,5-dimethyl-4-isoxazolyl.
2. A compound of claim 1 of Formula II
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug;
wherein R1 is a) \u2014(C1-C6)alkyl optionally substituted with \u2014CF3, b) \u2014C\u2261C\u2014CH3, c) \u2014CF3 or d) \u2014CH2O(C2-C4)alkyl; and n is one or two.
3. A compound of claim 2 wherein R1 is a) \u2014CH2CH2CH3, b) \u2014C\u2261C\u2014CH3 or c) \u2014CF3; and n is one.
4. A compound of claim 3 wherein R1 is a) \u2014CH2CH2CH3 or b) CF3.
5. A compound of claim 4 wherein R3 is \u2014(C1-C2)alkyl-NR4R5;
R4 and R5 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.
6. A compound of claim 5 wherein R3 is \u2014(C1-C2)alkyl-NR4R5;
R4 and R5 are each independently a) methyl or b) ethyl.
7. A compound of claim 3 wherein R3 is \u2014(C0-C2)alkyl-het;
het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl, d) piperazinyl, e) hexahydro-azepinyl, f) azabicyclo2.2.2oct-3-yl, g) azabicyclo3.2.1oct-3-yl, h) 3,6-diazabicyclo3.1.1heptyl, i) 2,5-diazabicyclo2.2.1heptyl, j) 1,2,5,6-tetrahydro-pyridinyl, k) azetidinyl, l) 1,4-diazabicyclo3.2.2nonanyl, m) 3,6-diazabicyclo3.2.2nonanyl, n) octahydro-pyrido1,2-apyrazinyl or o) hexahydro-1,4-diazepinyl;
the above het groups are optionally substituted with one or two R6;
R6 for each occurrence is independently a) methyl, b) ethyl or c) \u2014NR8R9;
R8 and R9 for each occurrence are independently methyl or ethyl.
8. A compound of claim 7 wherein R3 is \u2014(C0-C2)alkyl-het;
het is a) morpholinyl, b) piperidinyl, c) 1,2,5,6-tetrahydro-pyridinyl, d) azetidinyl or e) pyrrolidinyl;
the above het groups are optionally substituted with one or two R6;
R6 for each occurrence is independently a) methyl or b) ethyl.
9. A compound of claim 1 wherein R1 is a) \u2014CH2CH2CH3, b) \u2014C\u2261C\u2014CH3 or c) \u2014CF3;
R2 is a) methyl, b) ethyl, c) propyl, d) ethenyl or e) propenyl;
R3 is \u2014(C1-C2)alkyl-NR4R5;
R4 and R5 are each independently a) methyl or b) ethyl;
n is one.
10. A compound of claim 1 wherein R1 is a) \u2014CH2CH2CH3, b) \u2014C\u2261C\u2014CH3 or c) \u2014CF3;
R2 is a) methyl, b) ethyl, c) propyl, d) ethenyl or e) propenyl;
R3 is \u2014(C0-C2)alkyl-het;
het is a) morpholinyl, b) piperidinyl or c) pyrrolidinyl;
the above het groups are optionally substituted with one or two R6;
R6 for each occurrence is independently a) methyl or b) ethyl; and
n is one.
11. A compound of claim 6 selected from the group consisting of:
2-phenanthrenol, 7-5-(dimethylamino)methyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-;
2-phenanthrenol, 7-5-2-(dimethylamino)ethyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-;
2-phenanthrenol, 7-5-2-(dimethylamino)ethyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-; and
2-phenanthrenol, 7-5-2-(diethylamino)ethyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-.
12. A compound of claim 8 selected from the group consisting of:
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-5-2-(4-morpholinyl)ethyl-1,2,4-oxadiazol-3-ylmethoxy-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-ylmethoxy-2-(trifluoromethyl)-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-5-2-(1-piperidinyl)ethyl-1,2,4-oxadiazol-3-ylmethoxy-2-(1-propynyl)-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-5-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-1,2,4-oxadiazol-3-ylmethoxy-, (2R,4aS,10aR)-;
2-phenanthrenol, 7-5-2-(1-azetidinyl)ethyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-ylmethoxy-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-5-2-(1-piperidinyl)ethyl-1,2,4-oxadiazol-3-ylmethoxy-2-propyl-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-ylmethoxy-2-propyl-, (2R,4aS,10aR)-;
2-phenanthrenol, 7-5-2-(1-azetidinyl)ethyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-ylmethoxy-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-;
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-5-2-(1-piperidinyl)ethyl-1,2,4-oxadiazol-3-ylmethoxyl-2-(trifluoromethyl)-, (2R,4aS,10aR)-;
2-phenanthrenol, 7-5-2-(1-azetidinyl)ethyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-; and
2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-ylmethoxy-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-.
13. 2-Phenanthrenol, 7-5-methyl-1,2,4-oxadiazol-3-ylmethoxy-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-, a compound of claim 4.
14. A compound of claim 9 selected from the group consisting of:
phenanthren-2-ol, 7-(5-dimethylaminomethyl-1,2,4oxadiazol-3-ylmethoxy)-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,4aR,10aR)-; and
phenanthren-2-ol, 7-5-(2-dimethylaminoethyl)-1,2,4oxadiazol-3-ylmethoxy-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,4aR,10aR)-.
15. A compound of claim 10 selected from the group consisting of:
phenanthren-2-ol, 4a-ethyl-7-5-(2-morpholin-4-yl-ethyl)-1,2,4oxadiazol-3-ylmethoxy-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydro-,(2R,4aR,10aR)-; and
phenanthren-2-ol, 4a-ethyl-7-(5-piperidin-1-ylmethyl-1,2,4oxadiazol-3-ylmethoxy)-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydro-,(2R,4aR,10aR)-.
16. A method for the treatment of a disease or condition selected from the group consisting of obesity, diabetes, depression, anxiety, neurodegeneration and inflammatory disease in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
17. The method of claim 16 wherein the disease or condition is selected from the group consisting of obesity, diabetes, depression, anxiety and neurodegeneration.
18. The method of claim 17 wherein the condition is obesity.
19. The method of claim 18 which further comprises administering a \u03b23 agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist.
20. The method of claim 19 wherein the eating behavior modifying agent is orlistat or sibutramine.
21. The method of claim 17 wherein the disease is diabetes.
22. The method of claim 21 which further comprises administering an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, a sulfonylurea, glipizide, glyburide, or chlorpropamide.
23. The method of claim 16 wherein the disease is a inflammatory disease.
24. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.
25. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:
a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and
a second compound, said second compound being a \u03b23 agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist.
26. A kit comprising:
a) a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;
b) a second compound, said second compound being a \u03b23 agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist; and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and
c) a container for containing said first and second dosage forms; wherein the amounts of said first and second compounds result in a therapeutic effect.
27. A method for inducing weight loss in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, a prodrug of said compound a pharmaceutically acceptable salt of said compound or prodrug.
28. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:
a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and
a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, a sulfonylureas, glipizide, glyburide, or chlorpropamide.
29. A method for the treatment of an inflammatory disease in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
30. The method of claim 29 wherein the inflammatory disease is selected from the group consisting of arthritis, asthma, rhinitis and immunomodulation.